Literature DB >> 15585890

Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.

Juhua Zhou1, Mark E Dudley, Steven A Rosenberg, Paul F Robbins.   

Abstract

In recent clinical trials in patients with metastatic melanoma, adoptive transfer of tumor-reactive lymphocytes mediated the regression of metastatic tumor deposits. To better understand the role of individual T cell clones in mediating tumor regression, a 5' RACE technique was used to determine the distribution of TCR beta-chain V region sequences expressed in the transferred cells as well as in tumor samples and circulating lymphocytes from melanoma patients following adoptive cell transfer. We found that dominant T cell clones were present in the in vitro-expanded and transferred tumor-infiltrating lymphocyte samples and certain T cell clones including the dominant T cell clones persisted at relatively high levels in the peripheral blood of the patients that demonstrated clinical responses to adoptive immunotherapy. However, these dominant clones were either undetected or present at a very low level in the resected tumor samples used for tumor-infiltrating lymphocyte generation. These data demonstrated that there was selective growth and survival, both in vitro and in vivo, of individual T cell clones from a relatively small number of T cells in the original tumor samples. These results suggest that the persistent T cell clones played an active role in mediating tumor regression and that 5' RACE analysis may provide an important tool for the analysis of the role of individual T cell clones in mediating tumor regression. A similar analysis may also be useful for monitoring autoimmune responses.

Entities:  

Mesh:

Year:  2004        PMID: 15585890      PMCID: PMC2174603          DOI: 10.4049/jimmunol.173.12.7622

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire.

Authors:  N L La Gruta; I R Driel; P A Gleeson
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

3.  Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Authors:  Pierre-Yves Dietrich; Frédérique-Anne Le Gal; Valérie Dutoit; Mikäel J Pittet; Lydie Trautman; Alfred Zippelius; Isabelle Cognet; Valérie Widmer; Paul R Walker; Olivier Michielin; Philippe Guillaume; Thierry Connerotte; Francine Jotereau; Pierre G Coulie; Pedro Romero; Jean-Charles Cerottini; Marc Bonneville; Danila Valmori
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

4.  Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation by peptidomimetic opioid compound.

Authors:  P Narayan; R Pandey; V S Yadav; R Tandon; W Haq; M M Dhar; V K Singh
Journal:  Immunopharmacol Immunotoxicol       Date:  2003-05       Impact factor: 2.730

5.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

Review 6.  Cytokine control of memory T-cell development and survival.

Authors:  Kimberly S Schluns; Leo Lefrançois
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

7.  Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy.

Authors:  Martina Willhauck; Carmen Scheibenbogen; Michael Pawlita; Thomas Möhler; Eckhard Thiel; Ulrich Keilholz
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

9.  TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.

Authors:  Jayanthi Manne; Michael J Mastrangelo; Takami Sato; David Berd
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system.

Authors:  Tadashi Yokosuka; Kan Takase; Misao Suzuki; Yohko Nakagawa; Shinsuke Taki; Hidemi Takahashi; Takehiko Fujisawa; Hisashi Arase; Takashi Saito
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

View more
  22 in total

Review 1.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

3.  Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Authors:  Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

Review 4.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

5.  A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.

Authors:  Eiji Kobayashi; Eishiro Mizukoshi; Hiroyuki Kishi; Tatsuhiko Ozawa; Hiroshi Hamana; Terumi Nagai; Hidetoshi Nakagawa; Aishun Jin; Shuichi Kaneko; Atsushi Muraguchi
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

6.  Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.

Authors:  Xinglei Shen; Juhua Zhou; Karen S Hathcock; Paul Robbins; Daniel J Powell; Steven A Rosenberg; Richard J Hodes
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

Review 7.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

9.  Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection.

Authors:  Jacob T Minang; Matthew T Trivett; Diane L Bolton; Charles M Trubey; Jacob D Estes; Yuan Li; Jeremy Smedley; Rhonda Pung; Margherita Rosati; Rashmi Jalah; George N Pavlakis; Barbara K Felber; Michael Piatak; Mario Roederer; Jeffrey D Lifson; David E Ott; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

10.  A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Authors:  Yangbing Zhao; Qiong J Wang; Shicheng Yang; James N Kochenderfer; Zhili Zheng; Xiaosong Zhong; Michel Sadelain; Zelig Eshhar; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.